New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRI

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRI

New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcriSee more

New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcri

Orgovyx, Nubeqa, & Early Taxotere | 2021 Treatments In Review | Mark Scholz, MDSee more

Orgovyx, Nubeqa, & Early Taxotere | 2021 Treatments In Review | Mark Scholz, MD

Treatments for Advanced Prostate Cancer in 2022 | Evan Yu, MD | PCRISee more

Treatments for Advanced Prostate Cancer in 2022 | Evan Yu, MD | PCRI

New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRISee more

New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRI

What is Nubeqa for Prostate Cancer and How Does it Work? | Ask a Prostate Expert, Mark Scholz, MDSee more

What is Nubeqa for Prostate Cancer and How Does it Work? | Ask a Prostate Expert, Mark Scholz, MD

Comparing the Second Generation Hormone Therapies | Ask a Prostate Expert, Mark Scholz, MDSee more

Comparing the Second Generation Hormone Therapies | Ask a Prostate Expert, Mark Scholz, MD

Orgovyx: New FDA Approved Hormone Therapy | 2020: The Year In Review | Mark Scholz, MDSee more

Orgovyx: New FDA Approved Hormone Therapy | 2020: The Year In Review | Mark Scholz, MD

Nubeqa (Darolutamide), a Hormone Therapy | Ask a Prostate Expert, Mark Scholz, MDSee more

Nubeqa (Darolutamide), a Hormone Therapy | Ask a Prostate Expert, Mark Scholz, MD

Events